Pipeline
Innovative and creative portfolio across two pillars of growth: ADC and small molecule
Our Pipeline
Antibiotics
| Program | Indication | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Marketed | Partner | Details |
|---|---|---|---|---|---|---|---|---|---|
| Delpazolid Gram+ |
-DS-TB, MDR-TB -MRSA, VRE, -S. pneumoniae -NTM |
|
|
- Orphan Drug |
|||||
|
|
|
- L/O for China |
|||||||
Anti-fibrotics
| Program | Indication | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Marketed | Partner | Details |
|---|
Anti-coagulants
| Program | Indication | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Marketed | Partner | Details |
|---|---|---|---|---|---|---|---|---|---|
| LCB02-0133 Nokxaban,FXa Inhibitor |
|
|
L/O for global (Profit Sharing) |
||||||
|
|
|
Sub L/O for China |
|||||||
Immuno Oncology
| Program | Indication | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Marketed | Partner | Details |
|---|---|---|---|---|---|---|---|---|---|
| LCB39 STING agonist |
|
|
- I/O Targeted |
||||||
| LCB33 ENPP1 inhibitor |
|
|
Combi with ADCs |
||||||